المؤلفون: Sophie Clément, Pierre O. Chappuis, Alexandre Bodmer, Krisztian Homicsko, Yann Christinat, Melinda Charrier, Olivier Michielin, Petros Tsantoulis, Daniele Frisone, Thomas Alexander Mckee, Laure Thouvenin

المصدر: Cancer biology & therapy, vol. 21, no. 3, pp. 197-202
Cancer Biology and Therapy, Vol. 21, No 3 (2020) pp. 197-202

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, endocrine system diseases, ddc:616.07, Palbociclib, 03 medical and health sciences, 0302 clinical medicine, Cyclin D1, CDKN2A, Internal medicine, Gene duplication, medicine, neoplasms, ddc:616, Pharmacology, Retinoblastoma, business.industry, Letrozole, medicine.disease, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/genetics, Cyclin E/genetics, Cyclin-Dependent Kinase Inhibitor p16/genetics, Cystadenocarcinoma, Serous/drug therapy, Cystadenocarcinoma, Serous/genetics, Cystadenocarcinoma, Serous/pathology, Female, Gene Amplification, Humans, Letrozole/administration & dosage, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Local/genetics, Neoplasm Recurrence, Local/pathology, Oncogene Proteins/genetics, Ovarian Neoplasms/drug therapy, Ovarian Neoplasms/genetics, Ovarian Neoplasms/pathology, Piperazines/administration & dosage, Prognosis, Pyridines/administration & dosage, Retinoblastoma Binding Proteins/genetics, Sequence Deletion, Ubiquitin-Protein Ligases/genetics, CDK4/6 inhibitors, CDKN2A loss, Ovarian cancer, palbociblib, precision oncology, 030104 developmental biology, 030220 oncology & carcinogenesis, Molecular Medicine, Biomarker (medicine), business, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::352c882e2c41b9625dab34c1f829ff27
https://doi.org/10.1080/15384047.2019.1685291